RESMED INC SEC Filing
ResMed (RMD) received a Form 144 notice for a proposed insider sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ResMed (RMD) received a Form 144 notice for a proposed insider sale. The filing lists 8,011 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $2,000,773.19 and an approximate sale date of November 7, 2025.
The shares were acquired via an option originally granted on November 14, 2018, with acquisition and cash payment dated November 7, 2025. As context, the filing shows 145,966,294 shares outstanding. Recent activity disclosed in the notice includes three prior sales of 8,009 shares each on August 7, 2025, September 8, 2025, and October 7, 2025, with gross proceeds of $2,238,378.55, $2,227,590.42, and $2,265,332.03, respectively.
The notice indicates sales may occur using standard brokerage methods on a national exchange.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does ResMed (RMD)'s new Form 144 disclose?
What recent RMD insider sales are disclosed in the notice?
Who is the broker listed in the RMD Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.